Additionally, compared to free checkpoint inhibitors, nanomaterials loaded with PD-L1 can be decorated with tumor-targeting probes to decrease the dose while reducing side effects, and be sustainably released within the sites of interest (Teo et al., 2015; Wang C. et al., 2016). This evidence concerns the gene CD274 and neoplasm.